PALVELLA THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
353 W. LANCASTER AVENUE, WAYNE, PA, 19087
Mailing Address
353 W. LANCASTER AVENUE, WAYNE, PA, 19087
Phone
(484) 253-1461
Fiscal Year End
1231
EIN
300784346
Financial Overview
FY2025
$31.58M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 26, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 24, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Completed a transformative merger in December 2024 to focus exclusively on the QTORIN (rapamycin) anhydrous gel platform.
- QTORIN holds Orphan Drug Designation, offering potential tax credits and seven years of market exclusivity upon approval.
Insider Trading
STRONG SELL
3 insiders
11 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.